Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 10, 2012, Pages 1971-1977

  Bu, Rong ^a   Bavi, Prashant ^a   Abubaker, Jehad ^a   Jehan, Zeenath ^a   Al Haqawi, Wael ^a   Ajarim, Dahish ^b   Al Dayel, Fouad ^b   Uddin, Shahab ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b King Faisal Cancer Center   (Saudi Arabia)

Author keywords

A20 (TNFAIP3); CARD11; Deletion; DLBCL; Mutation; NF B; NHL therapy; Tissue microarray

Indexed keywords

CASPASE RECRUITMENT DOMAIN CONTAING PROTEIN 11; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REGULATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; ETHNIC GROUP; FEMALE; GENE AMPLIFICATION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MIDDLE EAST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION;

AGED; ARABS; BASE SEQUENCE; CARD SIGNALING ADAPTOR PROTEINS; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANYLATE CYCLASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NF-KAPPA B; NUCLEAR PROTEINS; PROGNOSIS;

EID: 84865719756     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.668286     Document Type: Article

References (53)

1. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-1174.
2. Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br JHaematol 2004;124:151-159.
3. Bazarbashi S. Cancer Incidence Report, Saudi Arabia, 2004. Riyadh: Saudi Cancer Registry; 2008.
4. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005;87: 163-208.
5. Basseres DS, Baldwin AS. Nuclear factor-kappaBand inhibitor of kappaBkinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817-6830.
6. Jost PJ, Ruland J. Aberrant NF-kappaBsignaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700-2707.
7. Cilloni D, Martinelli G, Messa F, et al. Nuclear factor kBas a target for new drug development in myeloid malignancies. Haematologica 2007;92:1224-1229.
8. Dutta J, Fan Y, Gupta N, et al. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006;25: 6800-6816.
9. Luo JL, Kamata H, Karin M. IKK/NF-kappaBsignaling: balancing life and death-a new approach to cancer therapy. JClin Invest 2005;115:2625-2632.
10. Burstein E, Duckett CS. Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol 2003;15:732-737.
11. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296.
12. Karin M. Nuclear factor-kappaBin cancer development and progression. Nature 2006;441:431-436.
13. Lawrence T, Bebien M, Liu GY, et al. IKKalpha limits macrophage NF-kappaBactivation and contributes to the resolution of inflammation. Nature 2005;434:1138-1143.
14. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaBin diffuse large B-cell lymphoma. Nature 2009;459:717-721.
15. Bavi P, Uddin S, Bu R, et al. The biological and clinical impact of inhibition of NF-Binitiated apoptosis in diffuse large B-cell lymphoma (DLBCL). JPathol 2011;224:355-366.
16. Bertin J, Wang L, Guo Y, et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. JBiol Chem 2001;276:11877-11882.
17. Gaide O, Martinon F, Micheau O, et al. Carma1, a CARDcontaining binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaBactivation. FEBSLett 2001;496:121-127.
18. Wang D, You Y, Case SM, et al. Arequirement for CARMA1 in TCR-induced NF-kappa Bactivation. Nat Immunol 2002;3:830-835.
19. Rawlings DJ, Sommer K, Moreno-Garcia ME. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 2006;6:799-812.
20. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large Bcell lymphoma. Science 2008;319:1676-1679.
21. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA2008;105:13520-13525.
22. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. JBiol Chem 2009;284:8217-8221.
23. Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaBand cell death responses in A20-deficient mice. Science 2000;289:2350-2354.
24. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaBsignalling. Nature 2004;430:694-699.
25. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of NHLs. Blood 2009;114:2467-2475.
26. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-716.
27. Chanudet E, Huang Y, Ichimura K, et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALTlymphoma. Leukemia 2010;24:483-487.
28. Novak U, Rinaldi A, Kwee I, et al. The NF-{kappa}Bnegative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009;113: 4918-4921.
29. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal Bcell lymphoma. JExp Med 2009;206:981-989.
30. Chanudet E, Ye H, Ferry J, et al. A20 deletion is associated with copy number gain at the TNFA/B/Clocus and occurs preferentially in translocation-negative MALTlymphoma of the ocular adnexa and salivary glands. JPathol 2009;217:420-430.
31. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone Bcell lymphoma. Genes Chromosomes Cancer 2008;47: 1-7.
32. Adam P, Haralambieva E, Greiner A, et al. CARMA1 and chromosomal translocations in extranodal marginal zone B-cell lymphomas of MALTtype or diffuse large B-cell lymphomas. Haematologica 2006; 91:1575-1576.
33. Egawa T, Albrecht B, Favier B, et al. Requirement for CARMA1 in antigen receptor-induced NF-kappa Bactivation and lymphocyte proliferation. Curr Biol 2003;13:1252-1258.
34. Pappu BP, Lin X. Potential role of CARMA1 in CD40-induced splenic Bcell proliferation and marginal zone Bcell maturation. Eur JImmunol 2006;36:3033-3043.
35. Re D, Hartlapp I, Greiner A, et al. Analysis of CARMA1/BCL10/MALT1 expression in Reed-Sternberg cells of classical Hodgkin lymphoma. Leuk Lymphoma 2008;49:362-364.
36. Schumacher MA, Schmitz R, Brune V, et al. Mutations in the genes coding for the NF-kappaBregulating factors IkappaBalpha and A20 are uncommon in nodular lymphocyte-predominant Hodgkin ' s lymphoma. Haematologica 2010;95:153-157.
37. Durkop H, Hirsch B, Hahn C, et al. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. JPathol 2003;200:229-239.
38. Bavi P, Prabhakaran SE, Abubaker J, et al. Prognostic significance of TRAILdeath receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRASalterations. Mol Cancer 2010;9:203.
39. Jaffe ES, Harris NL, Stein H, et al., editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARCPress; 2001. pp 10-12.
40. Bavi P, Abubaker J, Hussain A, et al. Reduced or absent cyclin Hexpression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol 2008;39:885-894.
41. Montagut C, Tusquets I, Ferrer B, et al. Activation of nuclear factor-kappa Bis linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006;13:607-616.
42. Charalambous MP, Lightfoot T, Speirs V, et al. Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br JCancer 2009;101: 106-115.
43. Legrand-Poels S, Schoonbroodt S, Piette J. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J2000;349:765-773.
44. McCarty KSJr., Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-721.
45. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259.
46. Jehan Z, Bavi P, Sultana M, et al. Frequent PIK3CAgene amplification and its clinical significance in colorectal cancer. JPathol 2009;219:337-346.
47. Robledo C, Garcia JL, Caballero D, et al. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer 2009;115:3728-3737.
48. Oshiro A, Tagawa H, Ohshima K, et al. Identification of subtypespecific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006;107:4500-4507.
49. Fujiwara SI, Yamashita Y, Nakamura N, et al. High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays. Leukemia 2008;22:1891-1898.
50. Narayan P, Holt B, Tosti R, et al. CARMA1 is required for Aktmediated NF-kappaBactivation in Tcells. Mol Cell Biol 2006;26: 2327-2336.
51. Dong G, Chanudet E, Zeng N, et al. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin Cancer Res 2011;17:1440-1451.
52. Montesinos-Rongen M, Schmitz R, Brunn A, et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaBpathway in primary CNSlymphoma. Acta Neuropathol 2010;120:529-535.
53. Naylor TL, Tang H, Ratsch BA, et al. Protein kinase Cinhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011;71:2643-2653.